



# Epilepsy Syndromes in Neonates/Infants/Children

Kullasate Sakpichaisakul, MD

Assistant Professor


Division of Neurology, Department of Pediatrics,  
Queen Sirikit National Institute of Child Health



# Outline

- Introduction to epilepsy syndromes (ILAE Task Force 2022)
- Epilepsy syndromes with onset in neonates/infants
- Epilepsy syndromes with onset in childhood

# Classification of Epilepsy (ILAE 2017)





# Epilepsy Syndrome


- A characteristic cluster of clinical and EEG features, often supported by specific etiological findings (structural, genetic, metabolic, immune, and infectious)
- The diagnosis of a syndrome in an individual with epilepsy frequently carries prognostic and treatment implications

# Epilepsy Syndrome: Electroclinical Features




Less Specific Clinical  
Entity

More Specific Clinical  
Entity



# Framework of Neonatal Seizures and Epilepsy Syndromes







# Seizure Type Classification

		Seizure type	Descriptors
<div>Critically ill or with</div>	<div>Seizure episodes (with EEG pattern)</div>	Automatisms	Unilateral Bilateral asymmetric Bilateral symmetric
		Clonic seizures	Focal Multifocal Bilateral
<div>amplitude</div>	<div>Seizure (with EEG)</div>	Epileptic spasms	Unilateral Bilateral asymmetric Bilateral symmetric
		Myoclonic seizures	Focal Multifocal Bilateral asymmetric Bilateral symmetric
		Tonic seizures	Focal Bilateral asymmetric Bilateral symmetric

A single predominant feature can be determined in the majority of cases.  
Pragmatically, classify seizures according to the predominant clinical manifestations



# Epilepsy Syndromes with Onset in Neonates and Infants

## ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions

Sameer M. Zuberi<sup>1</sup> | Elaine Wirrell<sup>2</sup>  | Elissa Yozawitz<sup>3</sup>  | Jo M. Wilmshurst<sup>4</sup>  |  
Nicola Specchio<sup>5</sup>  | Kate Riney<sup>6,7</sup>  | Ronit Pressler<sup>8,9</sup>  | Stephane Auvin<sup>10</sup>  |  
Pauline Samia<sup>11</sup>  | Edouard Hirsch<sup>12</sup>  | Santiago Galicchio<sup>13</sup> | Chahnez Triki<sup>14</sup> |  
O. Carter Snead<sup>15</sup> | Samuel Wiebe<sup>16</sup>  | J. Helen Cross<sup>17,18</sup>  | Paolo Tinuper<sup>19,20</sup> |  
Ingrid E. Scheffer<sup>21</sup>  | Emilio Perucca<sup>22,23</sup>  | Solomon L. Moshé<sup>24,25,26</sup>  |  
Rima Nabbout<sup>27</sup> 



# Epilepsy Syndromes with Onset in Neonates and Infants



## Self-limited epilepsies

- Self-limited neonatal epilepsy (SeLNE)
- Self-limited familial neonatal-infantile epilepsy (SeLFNIE)
- Self-limited infantile epilepsy (SeLIE)
- Genetic epilepsy with febrile seizures plus (GEFS+)
- Myoclonic epilepsy in infancy (MEI)

Epilepsy where there is likely to be spontaneous remission

## Developmental and epileptic encephalopathies (DEE)

- Early infantile developmental and epileptic encephalopathy (EIDEE)
- Epilepsy in infancy with migrating focal seizures (EIMFS)
- Infantile epileptic spasms syndrome (IESS)
- Dravet syndrome (DS)

## Etiology-specific syndromes

- *KCNQ2*-DEE
- Pyridoxine-dependent (*ALDH7A1*)-DEE (PD-DEE)
- Pyridox(am)ine 5'-Phosphate Deficiency (PNPO)-DEE (P5PD-DEE)
- *CDKL5*-DEE
- *PCDH19* clustering epilepsy
- Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)
- Sturge Weber syndrome (SWS)
- Gelastic seizures with hypothalamic hamartoma (GS-HH)

# Self-Limited Neonatal Epilepsy (SeLNE)




- Seizures occur between days of life 2-7
- Focal clonic or tonic seizures may alternate sides
- May evolve to bilateral tonic or clonic seizures
- Normal clinical exam and head size
- EEG: normal background with or without spikes
- Ictal EEG: initial attenuation of EEG followed by repetitive spikes
- Neuroimaging: normal
- AD inheritance
- KCNQ2 (80%), KCNQ3, SCN2A mutation
- Seizures remit by 6 months of age (mostly by 6 weeks of age)



# Self-Limited Neonatal Epilepsy (SeLNE)

(A)



# Epilepsy Syndromes with Onset in Neonates and Infants



## Self-limited epilepsies

- Self-limited neonatal epilepsy (SeLNE)
- Self-limited familial neonatal-infantile epilepsy (SeLFNIE)
- Self-limited infantile epilepsy (SeLIE)
- Genetic epilepsy with febrile seizures plus (GEFS+)
- Myoclonic epilepsy in infancy (MEI)

## Developmental and epileptic encephalopathies (DEE)

- Early infantile developmental and epileptic encephalopathy (EIDEE)
- Epilepsy in infancy with migrating focal seizures (EIMFS)
- Infantile epileptic spasms syndrome (IESS)
- Dravet syndrome (DS)

## Etiology-specific syndromes

- *KCNQ2*-DEE
- Pyridoxine-dependent (*ALDH7A1*)-DEE (PD-DEE)
- Pyridox(am)ine 5'-Phosphate Deficiency (PNPO)-DEE (P5PD-DEE)
- *CDKL5*-DEE
- *PCDH19* clustering epilepsy
- Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)
- Sturge Weber syndrome (SWS)
- Gelastic seizures with hypothalamic hamartoma (GS-HH)

Epilepsy where developmental impairment is related to both the underlying etiology independent of epileptiform activity and the epileptic encephalopathy



# Early-Infantile Developmental and Epileptic Encephalopathy (EIDEE)



- Seizure onset within first 3 months of life
- Tonic and/or myoclonic seizures
- Frequent seizures and drug resistant
- Abnormal neurological exams
- EEG: burst suppression or multifocal discharges
- Various etiologies included genetic, metabolic, and structural
- Moderate to profound developmental impairment

# Infantile Epileptic Spasms Syndrome (IESS)




- Formerly as West syndrome
- Epileptic spasms (flexor, extensor, mixed)
- Spasms occur between 1-24 months of age
- Developmental slowing, arrest, or regression
- Interictal EEG: hypsarrhythmia or multifocal spikes
- Ictal EEG shows electrodecremental response
- Various etiologies
- Carefully exam for tuberous sclerosis complex (TSC)
- Treatment: VGB for TSC, Steroid (ACTH or prednisolone) or combination therapy for non-TSC)




# Evolution of Hypsarrhythmia



Stage I: Multifocal spikes < 50%



Stage II: Bihemispheric sharp waves 50-90%





Stage III: Irregular bihemispheric sharp waves 90-100%

Poor interrater reliability;  
 $K = 0.40$



# Electrodecremental Response



# Evidence Based Treatment for Epileptic Spasms



Study	Outcome Measure	Steroids	VGB
UKISS 2004 (non-TSC patients)	Spasm cessation on days 14	72% (40/55)	54% (28/52)
	Sustained spasms control with no relapse until 12-14 months of age	40% (22/55)	37% (19/52)
PERC 2016	Cessation of spasms within 2 wks of therapy, with EEG resolution sustained at 3 months	49% (74/151)	36% (17/47)
		<b>Steroids alone</b>	<b>Combined steroid and VGB</b>
ICISS 2017	Cessation of spasms between day 14-42	57%	72%





# Combined VGB with Prednisolone vs VGB alone RCT


	Combined VGB with prednisolone (n = 17)	VGB alone (n = 24)	OR (95% CI)	p
<b>Primary outcome</b>				
Cessation of spasms from day 14 to 42	13/17 (77%)	8/24 (33%)	6.5 (1.7, 29.6)	0.009
<b>Secondary outcomes</b>				
Electroclinical response on day 14	8/14 (57%)	3/24 (13%)	9.3 (2.0, 54.3)	0.006
Electroclinical response on day 42	9/16 (56%)	9/22 (41%)	1.9 (0.5, 7.1)	0.351



## RESEARCH ARTICLE OPEN ACCESS

## Combination Therapy With Vigabatrin and Prednisolone Versus Vigabatrin Alone for Infantile Spasms

Rachata Boonkrongsak<sup>1,2</sup> | Kantapon Trongkamolchai<sup>1</sup> | Sirorat Suwannachote<sup>1,2</sup> | Somjit Sri-Udomkajorn<sup>1,2</sup> | Raviwan Wittawassamrankul<sup>3</sup> | Ravindra Arya<sup>4,5</sup>  | Kullasate Sakpichaisakul<sup>1,2</sup> 



**FIGURE 2** | Kaplan-Meier graph for the probability of cessation of spasms between the treatment allocation groups. VGB = vigabatrin.




# Dravet Syndrome

- Seizures present in 1-20 months of life
  - Recurrent hemiclonic seizures febrile or afebrile seizures
  - Prolonged seizures triggered by fever
- Normal growth and development as infants
- Drug resistant seizures evolved to myoclonic seizures, atypical absence, GTC, focal to bilateral GTC
- Initial EEG: normal prior to age 2 years
- EEG showed interictal discharges after 2 yo
- Developmental decline after 1-2 years of age, speech delay
- Genetic etiology: 70%-80% have **SCN1A** mutations



# Treatment Algorithm for Dravet Syndrome



# Epilepsy Syndromes with Onset in Neonates and Infants



## Self-limited epilepsies

- Self-limited neonatal epilepsy (SeLNE)
- Self-limited familial neonatal-infantile epilepsy (SeLFNIE)
- Self-limited infantile epilepsy (SeLIE)
- Genetic epilepsy with febrile seizures plus (GEFS+)
- Myoclonic epilepsy in infancy (MEI)

## Developmental and epileptic encephalopathies (DEE)

- Early infantile developmental and epileptic encephalopathy (EIDEE)
- Epilepsy in infancy with migrating focal seizures (EIMFS)
- Infantile epileptic spasms syndrome (IESS)
- Dravet syndrome (DS)

## Etiology-specific syndromes

- *KCNQ2*-DEE
- Pyridoxine-dependent (*ALDH7A1*)-DEE (PD-DEE)
- Pyridox(am)ine 5'-Phosphate Deficiency (PNPO)-DEE (P5PD-DEE)
- *CDKL5*-DEE
- *PCDH19* clustering epilepsy
- Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)
- Sturge Weber syndrome (SWS)
- Gelastic seizures with hypothalamic hamartoma (GS-HH)

Syndromes due to specific genetic, structural, immune, and infectious etiologies where there are consistent electroclinical features, management and prognostic implications

# GLUT1DS



- Cerebral “energy crisis”
- Symptoms develop in an age-specific pattern
- Infancy
  - Early onset absence epilepsy (< 4 yo), Myoclonic-atonic seizures
  - Paroxysmal eye-head movement
- Movement disorders: paroxysmal or persistent
  - Ataxia, spastic, dystonia
- Acquired microcephaly and cognitive impairment
- LP shows hypoglycorrachia (< 40 mg/dL)
- SLC2A1 mutation or deletion/duplication
- Early ketogenic diet treatment: better intellectual outcomes

# Epilepsy Syndromes with Onset in Childhood


Epilepsia®



SPECIAL REPORT


## International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions

Nicola Specchio<sup>1</sup> | Elaine C. Wirrell<sup>2</sup> | Ingrid E. Scheffer<sup>3</sup> | Rima Nabbout<sup>4</sup> |  
Kate Riney<sup>5,6</sup> | Pauline Samia<sup>7</sup> | Marilisa Guerreiro<sup>8</sup> | Sam Gwer<sup>9</sup> |  
Sameer M. Zuberi<sup>10</sup> | Jo M. Wilmschurst<sup>11</sup> | Elissa Yozawitz<sup>12</sup> | Ronit Pressler<sup>13</sup> |  
Edouard Hirsch<sup>14</sup> | Sam Wiebe<sup>15</sup> | Helen J. Cross<sup>16</sup> | Emilio Perucca<sup>17,18</sup> |  
Solomon L. Moshé<sup>19</sup> | Paolo Tinuper<sup>20,21</sup> | Stéphane Auvin<sup>22</sup>





# Self-Limited Focal Epilepsies






# Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTs)




- Formerly BECTs, benign rolandic epilepsy (BRE)
- Most common idiopathic focal epilepsy
- Seizure: brief, focal clonic or tonic seizures of the throat/tongue
- May evolve to a focal to bilateral GTC seizures
- Age at onset: 3-13 years, peak 9-10
- EEG: normal background with centrotemporal spikes activate in drowsiness and sleep are mandatory
- Mild cognitive impairment, LD but no regression
- Treat VS not to treat
- Seizures respond well with ASMs and resolve by puberty


# Normal Awake Recording



# Drowsiness, Centrotemporal spikes




# Sleep, Centrotemporal spikes





# Genetic Generalized Epilepsies






# Absence Epilepsy



- Childhood absence epilepsy (CAE)
  - Onset 4-10 years
  - Absence seizures occur daily but GTC seizure rarely occur
- Juvenile absence epilepsy (JAE)
  - Onset 9-13 years
  - GTC seizures commonly occur (80%) but absence seizures occur less than daily
- Induced by hyperventilation
- EEG:
  - CAE: 2.5-4 Hz generalized spike-wave (GSW)
  - JAE: 3-5.5 Hz irregular generalized spike-wave
- If no GSW is seen within hyperventilation for 3 min in an untreated patient, CAE or JAE can be excluded
- Treatment: valproate, ethosuximide, lamotrigine



# Generalized 3 Hz spike-waves complexes




# Lennox-Gastaut Syndrome (LGS)



- DEE with wide range of etiologies
- Multiple types of DRE with onset <18 yo
- Seizures begin between 18 mo – 8 yo (peak 3-5 yo)
- Tonic seizure is mandatory
- Other seizures include atypical absence, atonic, myoclonic, etc
- Cognitive and behavioral impairment
- EEG showed generalized  $\leq 2.5$  Hz slow spike-wave and generalized PFA

# Generalized 1.5-2.5 Hz Slow spike-wave



# Paroxysmal Fast Activity (PFA)




[SENS \*20 HF \*50RP TC \*0.1 CAL \*50]



# Tonic Seizure




[SENS \*20 HF \*50RP TC \*0.1 CAL \*50]






# Treatment Algorithm for a Newly Diagnosed LGS



# DEE- or EE- with spike and wave activation in sleep (SWAS)



## EE or DEE with spike-wave activation in sleep



# DEE or EE-SWAS




- Formerly as Landau-Kleffner syndrome (LKS), CSWS, or ESES
- Cognitive, language, behavioral, or motor **regression or plateauing temporally related to SWAS on EEG**
- EE-SWAS: pre-existing normal development with and an activation of 1.5-2 Hz spike and wave complexes in NREM sleep
- DEE-SWAS: pre-existing neurodevelopmental disorders and a documented persisting **worsening of various combinations of development**

# DEE or EE-SWAS



- Seizure onset: 2-12 yo (peak 4-5 yo)
- Regresison in cognitve, behavioral, or psychiatric functioning is the cardinal symptoms
- Sleep EEG is mandatory
- EEG shows spike-and-wave activation in sleep
- Thalamic injury in early life and bilateral perisylvian polymicrogyria are risk factors
- Duration and etiology are the most important predictors of outcome
- Poor outcomes are associated with younger onset or present > 2 y
- Treatment: steroids, clobazam

# DEE or EE-SWAS: Awake EEG



(A)



# DEE or EE-SWAS: Sleep EEG



(B)



# Conclusions

- Each syndrome has mandatory seizure types, EEG features, age at onset, and findings from key investigations
- Syndromes can be divided into self-limited focal epilepsies, generalized epilepsies, and DEE
- Precise identification of an epileptic syndrome can provide useful information on prognosis and management





# Special Thanks



กุมารเวชศาสตร์  
รพ. มหาราชนครราชสีมา



Boston  
Children's  
Hospital

Until every child is well™



BRIGHAM HEALTH

BRIGHAM AND  
WOMEN'S HOSPITAL



Cincinnati  
Children's™  
changing the outcome together

